

Investor Information Sheet

Company Name:	StemBond Technologies
Funding Stage:	Pre-seed
Investment Opportunity:	Preparing for next round in 9-12 months
Web address:	www.StemBond.tech



Unlocking Cell Culture for Regenerative Medicine

The Problem: Advanced regenerative medicine requires advanced cell culture to control the fate and function of vital therapeutic cells.

Current cell culture platforms, however, are unable to control the maintenance, expansion and fate of many key cell types. Traditional approaches have focused on biochemistry, requiring cell types that respond favourably to available culture substrates.

An essential key to harnessing cell fate and function, however, is the mechanical environment. Without control over the mechanical properties of culture substrates, many cell types quickly undergo loss-of-function such as senescence, population heterogeneity and phenotypic drift.

The Solution: StemBond Technologies is leveraging advanced materials science to transform scalable cell culture, tissue engineering and regenerative medicine. Our physics-based solutions alleviate cell culture bottlenecks experienced by those seeking to harness cell function.

With precise and reproducible control over extracellular mechanics, StemBond Technologies delivers more stable cultures, less phenotypic drift and increased uniformity.

Milestones to date

May 2022: Innovate UK 'Health Tech Program' Grant: £25,000

May 2022: Start Codon and Meltwind (Jonathan Milner) Investment: £250,000 & £300,000 respectively

June 2022: Began MTA based pilot studies with Bit.bio and Axol Biosciences

Sept 2022: Moved into hosted lab and office space in the Stem Cell Institute (8 months)

Sept 2022: Cambridge Enterprise Seed Funds Fast50: £75,000

Funding Opportunity

StemBond Technologies are in the process of closing an extended pre-seed round. We are now building relationships in preparation of our next round in 9-12 months.

References & Patents:

- Patent (licenced from Cambridge Enterprise): WO2019115814 - TUNEABLE CELL SUBSTRATES
- 'StemBond hydrogels control the mechanical microenvironment for pluripotent stem cells' Nature Comms 12, Article number 6132 (2021)
- 'Niche stiffness underlies the ageing of central nervous system progenitor cells' Nature, 573, 130-134 (2019)

Management Team



Dr. Andrew Hodgson, CEO & Co-Founder

Although originally trained as a physicist, Andrew's ambition was to combine physics and technology to create a new type of therapeutic company. While a PhD student then postdoctoral researcher at Cambridge University, Andrew studied entrepreneurship, biotechnology and stem cell biology.



Dr. Kevin Chalut, CSO & Co-Founder

Kevin was originally trained as a physicist though, through his postdoctoral work, he became fascinated by the impact of physics and mechanics in cell function and fate decisions. As Professor and Group Leader at the Stem Cell Institute, Kevin became a key figure in the field of mechano-biology.

For further information please contact:

Dr. Amanda Wooding Investment Director

Amanda.wooding@enterprise.cam.ac.uk

